Imaging in smoldering (asymptomatic) multiple myeloma: Past, present and future;Bildgebung bei "smoldering" (asymptomatischem) multiplem Myelom: Vergangenheit, Gegenwart und Zukunft

Radiologe

Volumn 54, Issue 6, 2014, Pages 572-581

  Bhutani, M ^a   Landgren, O ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Computed tomography; Magnetic resonance imaging; Positron emission tomography; Skeletal survey; Survival

Indexed keywords

ASYMPTOMATIC DISEASE; BONE MARROW NEOPLASMS; DIAGNOSTIC IMAGING; HUMAN; MULTIPLE MYELOMA; TRENDS;

ASYMPTOMATIC DISEASES; BONE MARROW NEOPLASMS; DIAGNOSTIC IMAGING; HUMANS; MULTIPLE MYELOMA;

EID: 84903524694     PISSN: 0033832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00117-014-2694-7     Document Type: Article

References (55)

1. Landgren O, Waxman AJ (2010) Multiple myeloma precursor disease. JAMA 304:2397-2404
2. Dimopoulos M, Kyle R, Fermand JP et al (2011) Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood 117:4701-4705
3. Waxman AJ, Kuehl M, Balakumaran A et al (2010) Smoldering (asymptomatic) multiple myeloma: revisiting the clinical dilemma and looking into the future. Clin Lymphoma Myeloma Leuk 10:248-257
4. Perez-Persona E, Vidriales MB, Mateo G et al (2007) New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood 110:2586-2592
5. Dispenzieri A, Kyle RA, Katzmann JA et al (2008) Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 111:785-789
6. Gonsalves WI, Rajkumar SV, Gupta V et al (2014) Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma. Leukemia
7. Kyle RA, Remstein ED, Therneau TM et al (2007) Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 356:2582-2590
8. Neben K, Jauch A, Hielscher T et al (2013) Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load. J Clin Oncol 31:4325-4332
9. Rajkumar SV, Gupta V, Fonseca R et al (2013) Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. Leukemia 27:1738-1744
10. Mateos MV, Hernandez MT, Giraldo P et al (2013) Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med 369:438-447
11. Wisloff F, Andersen P, Andersson TR et al (1991) Incidence and follow-up of asymptomatic multiple myeloma. The myeloma project of health region I in Norway. II. Eur J Haematol 47:338-341
12. D'Arena G, Gobbi PG, Broglia C et al (2011) Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study. Leuk Lymphoma 52:771-775
13. Hillengass J, Bauerle T, Bartl R et al (2011) Diffusion-weighted imaging for non-invasive and quantitative monitoring of bone marrow infiltration in patients with monoclonal plasma cell disease: a comparative study with histology. Br J Haematol 153:721-728
14. Walker R, Barlogie B, Haessler J et al (2007) Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol 25:1121-1128
15. Zamagni E, Patriarca F, Nanni C et al (2011) Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood 118:5989-5995
16. Dimopoulos M, Terpos E, Comenzo RL et al (2009) International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma. Leukemia 23:1545-1556
17. Edelstyn GA, Gillespie PJ, Grebbell FS (1967) The radiological demonstration of osseous metastases. Experimental observations. Clin Radiol 18:158-162
18. Murray I, Kalemis A, Glennon J et al (2010) Time-of-flight PET/CT using low-activity protocols: potential implications for cancer therapy monitoring. Eur J Nucl Med Mol Imaging 37:1643-1653
19. Hara AK, Paden RG, Silva AC et al (2009) Iterative reconstruction technique for reducing body radiation dose at CT: feasibility study. AJR Am J Roentgenol 193:764-771
20. Masuda Y, Kondo C, Matsuo Y et al (2009) Comparison of imaging protocols for 18F-FDG PET/CT in overweight patients: optimizing scan duration versus administered dose. J Nucl Med 50:844-848
21. Baur-Melnyk A, Buhmann S, Becker C et al (2008) Whole-body MRI versus whole-body MDCT for staging of multiple myeloma. AJR Am J Roentgenol 190:1097-1104
22. Gleeson TG, Moriarty J, Shortt CP et al (2009) Accuracy of whole-body low-dose multidetector CT (WBLDCT) versus skeletal survey in the detection of myelomatous lesions, and correlation of disease distribution with whole-body MRI (WBMRI). Skeletal Radiol 38:225-236
23. Bauerle T, Hillengass J, Fechtner K et al (2009) Multiple myeloma and monoclonal gammopathy of undetermined significance: importance of whole-body versus spinal MR imaging. Radiology 252:477-485
24. Ghanem N, Lohrmann C, Engelhardt M et al (2006) Whole-body MRI in the detection of bone marrow infiltration in patients with plasma cell neoplasms in comparison to the radiological skeletal survey. Eur Radiol 16:1005-1014
25. Horger M, Weisel K, Horger W et al (2011) Whole-body diffusion-weighted MRI with apparent diffusion coefficient mapping for early response monitoring in multiple myeloma: preliminary results. AJR Am J Roentgenol 196:W790-W795
26. Giles SL, Messiou C, Collins DJ et al (2014) Whole-body diffusion-weighted MR imaging for assessment of treatment response in myeloma. Radiology 131529
27. Hillengass J, Zechmann C, Bauerle T et al (2009) Dynamic contrast-enhanced magnetic resonance imaging identifies a subgroup of patients with asymptomatic monoclonal plasma cell disease and pathologic microcirculation. Clin Cancer Res 15:3118-3125
28. Tian J, Fu L, Yin D et al (2014) Does the novel integrated PET/MRI offer the same diagnostic performance as PET/CT for oncological indications? PLoS One 9:e90844
29. Tofts PS, Brix G, Buckley DL et al (1999) Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 10:223-232
30. Bhutani M, Turkbey B, Tan E et al (2014) Bone marrow angiogenesis in myeloma and its precursor disease: a prospective clinical trial. Leukemia 28:413-416
31. Hylton N (2006) Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker. J Clin Oncol 24:3293-3298
32. Wasser K, Moehler T, Neben K et al (2004) Dynamic MRI of the bone marrow for monitoring multiple myeloma during treatment with thalidomide as monotherapy or in combination with CED chemotherapy. Rofo 176:1285-1295
33. Nonomura Y, Yasumoto M, Yoshimura R et al (2001) Relationship between bone marrow cellularity and apparent diffusion coefficient. J Magn Reson Imaging 13:757-760
34. Dimopoulos MA, Moulopoulos A, Smith T et al (1993) Risk of disease progression in asymptomatic multiple myeloma. Am J Med 94:57-61
35. Moulopoulos LA, Dimopoulos MA, Smith TL et al (1995) Prognostic significance of magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol 13:251-256
36. Mariette X, Zagdanski AM, Guermazi A et al (1999) Prognostic value of vertebral lesions detected by magnetic resonance imaging in patients with stage I multiple myeloma. Br J Haematol 104:723-729
37. Hillengass J, Fechtner K, Weber MA et al (2010) Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol 28:1606-1610
38. Dhodapkar MV, Sexton R, Waheed S et al (2014) Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). Blood 123:78-85
39. Merz M, Hielscher T, Wagner B et al (2014) Predictive value of longitudinal whole-body magnetic resonance imaging in patients with smoldering multiple myeloma. Leukemia
40. Hillengass J, Ayyaz S, Kilk K et al (2012) Changes in magnetic resonance imaging before and after autologous stem cell transplantation correlate with response and survival in multiple myeloma. Haematologica 97:1757-1760
41. Bartel TB, Haessler J, Brown TL et al (2009) F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood 114:2068-2076
42. Castellani M, Carletto M, Baldini L et al (2010) The prognostic value of F-18 fluorodeoxyglucose bone marrow uptake in patients with recent diagnosis of multiple myeloma: a comparative study with Tc-99m sestamibi. Clin Nucl Med 35:1-5
43. Usmani SZ, Mitchell A, Waheed S et al (2013) Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3. Blood 121:1819-1823
44. Derlin T, Weber C, Habermann CR et al (2012) 18F-FDG PET/CT for detection and localization of residual or recurrent disease in patients with multiple myeloma after stem cell transplantation. Eur J Nucl Med Mol Imaging 39:493-500
45. Nanni C, Zamagni E, Celli M et al (2013) The value of 18F-FDG PET/CT after autologous stem cell transplantation (ASCT) in patients affected by multiple myeloma (MM): experience with 77 patients. Clin Nucl Med 38:e74-e79
46. Agool A, Schot BW, Jager PL et al (2006) 18F-FLT PET in hematologic disorders: a novel technique to analyze the bone marrow compartment. J Nucl Med 47:1592-1598
47. Dankerl A, Liebisch P, Glatting G et al (2007) Multiple Myeloma: Molecular Imaging with 11C-Methionine PET/CT - Initial Experience. Radiology 242:498-508
48. Durie BG, Waxman AD, D'Agnolo A et al (2002) Whole-body (18)F-FDG PET identifies high-risk myeloma. J Nucl Med 43:1457-1463
49. Larsen JT, Kumar SK, Dispenzieri A et al (2013) Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. Leukemia 27:941-946
50. Rajkumar SV, Larson D, Kyle RA (2011) Diagnosis of smoldering multiple myeloma. N Engl J Med 365:474-475
51. Dispenzieri A, Stewart AK, Chanan-Khan A et al (2013) Smoldering multiple myeloma requiring treatment: time for a new definition? Blood 122:4172-4181
52. Hanrahan CJ, Christensen CR, Crim JR (2010) Current concepts in the evaluation of multiple myeloma with MR imaging and FDG PET/CT. Radiographics 30:127-142
53. Regelink JC, Minnema MC, Terpos E et al (2013) Comparison of modern and conventional imaging techniques in establishing multiple myeloma-related bone disease: a systematic review. Br J Haematol 162:50-61
54. Hutchison GB, Shapiro S (1968) Lead time gained by diagnostic screening for breast cancer. J Natl Cancer Inst 41:665-681
55. Feinleib M, Zelen M (1969) Some pitfalls in the evaluation of screening programs. Arch Environ Health 19:412-415